Scholar Rock Holding Corporation
SRRK
Rang în acțiuni
#3435
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to... Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
Preț acțiune
$41.61
Capitalizare de piață
$5.07B
Schimbare (1 zi)
3.40%
Schimbare (1 an)
49.03%
Țară
US
Tranzacționează Scholar Rock Holding Corporation (SRRK)
Categorie
Healthcare
Raport P/S pentru Scholar Rock Holding Corporation (SRRK)
Raport P/S la data de October 2026 TTM: 0.00
Conform celor mai recente rapoarte financiare și prețului acțiunilor Scholar Rock Holding Corporation, raportul P/S actual (TTM) este 0.00. La sfârșitul anului 2023, compania avea un P/S de 0.00.
Istoricul raportului P/S pentru Scholar Rock Holding Corporation din 2016 până în 2026
Raport P/S la sfârșitul fiecărui an
| An | Raport P/S | Schimbă |
|---|---|---|
| 2026 (TTM) | 0.00 | 0.00% |
| 2024 | 0.00 | 0.00% |
| 2023 | 0.00 | -100.00% |
| 2022 | 16.25 | -66.46% |
| 2021 | 48.47 | -49.95% |
| 2020 | 96.83 | 446.72% |
| 2019 | 17.71 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | -100.00% |
| 2016 | 732.28 | 0.00% |
Raport P/S pentru companii similare sau competitoare
| Companie | Raport P/S | Diferență raport P/S | Țara |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 3.96 | - |
AU
|
|
| - | - |
CH
|
|
| 10.15 | - |
NL
|
